<DOC>
	<DOCNO>NCT00877773</DOCNO>
	<brief_summary>The goal clinical research study learn temsirolimus help control advance cancer patient also PI3K mutation and/or PTEN loss . The safety drug also test .</brief_summary>
	<brief_title>Phosphatidylinositol 3 Kinase Mammalian Target Rapamycin ( PI3K-mTOR ) Advanced Cancer Patients</brief_title>
	<detailed_description>The Study Drug : Temsirolimus design block growth cancer cell , may cause cancer cell die . Study Drug Administration : If find eligible take part study , receive temsirolimus needle vein Days 1 , 8 , 15 , 22 4-week study cycle . On Day 1 Cycle 1 , study drug give 60 minute . If tolerate study drug well Day 1 Cycle 1 , give 30 minute schedule administration date long still tolerate well . If dose well tolerate , dose reduce future study visit . You receive Benadryl ( diphenhydramine ) similar drug vein help prevent side effect 30 minute receive study drug . Study Visits : One ( 1 ) time week ( day study drug give ) , follow test procedure perform : - Your weight vital sign measure . - You ask drug may take side effect may . - Blood ( 2 teaspoon time ) drawn pharmacodynamic ( PD ) test . PD test measure level study drug body may affect disease . This blood drawn follow time : At 8 hour ( +/- 3 hour ) dose At 24 hour ( +/- 3 hour ) dose At 72 hour ( +/- 24 hour ) dose Every 2 week , blood ( 2 teaspoon ) draw routine test . Every 4 week , physical exam ; woman able become pregnant also blood ( 1 teaspoon ) pregnancy test . Every 8 week , CT scan , MRI scan , and/or PET/CT scan check status disease . Length Study : You study long benefiting disease stable . You take study disease get bad , intolerable side effect , study doctor think best interest . End-of-Study Visit : After finish take study drug , follow test procedure perform : - You physical exam , include measurement weight vital sign . - You ask drug may take side effect may . This investigational study . Temsirolimus FDA-approved commercially available treatment advance renal cancer . Its use type cancer investigational . Up 65 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients pathologically confirm advanced metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy improve survival least 3 month ( unless temsirolimus indicated standard treatment disease ) . 2 . Patients must evaluable tumor ( ) document PIK3 mutation and/or PTEN loss . 3 . Patients must creatinine &lt; /= 3 X upper limit normal ( ULN ) ; absolute neutrophil count &gt; /= 1,000/mL ; platelet &gt; /= 50,000 ; bilirubin &lt; /= 3.0 gm/dL . Except patient liver metastasis : total bilirubin &lt; /= 5 ULN . 4 . Women childbearing potential must negative baseline blood pregnancy test . Women men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) duration study . 5 . Patients must antitumor agent least 5 half life agent 4 wks last day treatment , whichever short . For cytotoxic therapy , patient treatment 3 week . 6 . Patients may receive experimental agent FDA approve . 7 . Ability understand willingness sign write consent document . 8 . Treatment study may begin within 24 hour Phase 0 dose Temsirolimus . 1 . Pregnant lactating woman . 2 . Patients creatinine clearance &lt; 10 mL/min 3 . Patients know hypersensitivity component metabolites drug product . 4 . Patients major surgery within 30 day prior enter study . 5 . Patients inhibitor inducer CYP3A4 metabolism inhibitor inducer stop unless clinically contraindicate . See section 6 ( Concomitant Medications ) Appendix E protocol detail .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>Advanced Cancer genetic mutation</keyword>
	<keyword>Phosphoinositides 3-kinase</keyword>
	<keyword>PI3K</keyword>
	<keyword>PIK3 mutation</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>CCI-779</keyword>
	<keyword>Torisel</keyword>
	<keyword>mTOR inhibitor</keyword>
</DOC>